A new urine test has demonstrated promising results in a National Health Service trial, identifying more than 90% of bladder cancer cases, according to a BBC News report. The test, which analyzes genetic material shed into urine by cancerous cells, could significantly aid in the early detection of the disease and help manage diagnostic waiting lists.
Developed by the University of Birmingham with funding from Cancer Research UK (CRUK), the test examines over 450 DNA mutations across 23 genes that are associated with bladder cancer. In the NHS trial, the Galeas urine test correctly identified 92% of bladder cancer cases. For patients receiving a negative result, the test indicated a more than 99% probability that they did not have bladder cancer.
Bladder cancer is more prevalent in men over the age of 60, with blood in the urine being a primary symptom. The severity of the disease depends on its size and whether it has spread. Early detection and treatment are crucial for improving patient outcomes.
While the urine test is not intended to replace cystoscopies, it could serve as a valuable tool for prioritizing patients who require urgent investigation. Each year, more than 300,000 cystoscopies are performed in the UK, and some areas face considerable waiting times for the procedure. The test's ability to flag high-risk individuals could help streamline the diagnostic process.
Professor Richard Bryan, a co-author of the study from the University of Birmingham, expressed enthusiasm about the test's performance in a real-world patient setting after years of development. The test has been commercialized by Nonacus under a licensing agreement, which includes revenue sharing with the University and CRUK.
Michelle Mitchell of CRUK emphasized the importance of finding faster and less invasive methods for cancer diagnosis or exclusion, noting that many individuals experience delays in receiving a bladder cancer diagnosis. She stated that while the test is in its early stages and requires further research, its potential is vital in addressing these delays.